FIELD: biotechnology.
SUBSTANCE: proposed RNA-aptamer is a 57-unit mixed-type oligonucleotide having the nucleotide sequence GGGAGGACGAUGCGGUGUUUUCUGAGUACAUCUCUGCCCCACCCUU GUUUACCCCCA, where A, G are ribonucleotides, U, C are 2'-desoxy-2'-fluoro-ribonucleotides, has the ability to recognise autoantibodies specific to disseminated sclerosis.
EFFECT: characterised invention binds specifically and highly affine with autoantibodies specific to disseminated sclerosis, and can be used for the diagnostics of disseminated sclerosis.
3 dwg, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| RNA-APTAMER WITH ABILITY TO LEARNRECOGNIZE AUTOANTIBODIES, CHARACTERISTIC FOR MULTIPLE SCLEROSIS | 2017 |
|
RU2644229C1 |
| CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID MOLECULES THAT MEDIATE RNA INTERFERENCE | 2006 |
|
RU2418068C2 |
| APTAMERIC THERAPEUTIC AGENTS APPLICABLE FOR TREATING COMPLEMENT-RELATED DISORDERS | 2006 |
|
RU2406507C2 |
| TREATMENT OF CNS DISORDERS | 2007 |
|
RU2426544C2 |
| DNA APTAMER THAT SPECIFICALLY BINDS TO HUMAN DICKKOPF-1 PROTEIN | 2023 |
|
RU2814580C1 |
| COMPLEMENT-BINDING APTAMERS AND C5 AGENTS APPLICABLE FOR TREATING OCULAR DISORDERS | 2007 |
|
RU2477137C2 |
| METHOD FOR DETECTION OF TARGETS ASSOCIATED WITH CERTAIN DIAGNOSIS, IN BLOOD OF PATIENTS BASED ON DNA-APTAMER | 2017 |
|
RU2685936C2 |
| METHOD FOR ISOLATION AND ANALYSIS OF EXOSOMES | 2022 |
|
RU2788198C1 |
| METHOD FOR ASSESSING THE AFFINITY OF AN OLIGONUCLEOTIDE | 2018 |
|
RU2700584C1 |
| INHIBITORS OF SIGNAL TRANSMISSION OF TRANSFORMING GROWTH FACTORS (TGF-R) FOR TREATMENT OF CNS DISORDERS | 2005 |
|
RU2385933C2 |
